Geoffrey Harms, MD | |
1201 S Miller St Ste A, Wenatchee, WA 98801-3201 | |
(509) 663-8711 | |
Not Available |
Full Name | Geoffrey Harms |
---|---|
Gender | Male |
Speciality | Interventional Cardiology |
Experience | 42 Years |
Location | 1201 S Miller St Ste A, Wenatchee, Washington |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1891720132 | NPI | - | NPPES |
P01256404 | Other | WA | RR MEDICARE WVH |
1891720132 | Medicaid | WA | |
315814 | Other | WA | WVH LNI |
Facility Name | Location | Facility Type |
---|---|---|
Central Washington Hospital | Wenatchee, WA | Hospital |
Mid Valley Hospital | Omak, WA | Hospital |
Samaritan Hospital | Moses lake, WA | Hospital |
Lake Chelan Community Hospital | Chelan, WA | Hospital |
Three Rivers Hospital | Brewster, WA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Central Washington Health Services Association | 4880504596 | 645 |
News Archive
The United States Food and Drug Administration (FDA) will be looking at the behavior and health of 40,000 smokers aged 12 and older to study the effects of new tobacco regulations.
A brief period of postnatal visual deprivation, when early in life, drives a rewiring of the brain areas involved in visual processing, even if the visual restoration is completed well before the baby reaches one year of age, researchers at the University of Trento, McMaster University, and the University of Montreal revealed today in Current Biology.
Abraxis BioScience, Inc., a fully integrated, global biotechnology company, today announced that Taiho Pharmaceutical Co., Ltd. has received approval from the Ministry of Health, Labor and Welfare to market ABRAXANE IV Infusion 100 mg, Paclitaxel Injection (Suspension with Albumin), for use in the treatment of breast cancer. The New Drug Application (J-NDA) for ABRAXANE was filed with the Ministry of Health, Labor and Welfare in 2008.
One year after being hospitalized in intensive care, patients have reduced bone mass that puts them at greater risk for fractures, according to a new study published online ahead of print in the American Journal of Respiratory and Critical Care Medicine.
› Verified 2 days ago
Entity Name | Central Washington Health Services Association |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1801937453 PECOS PAC ID: 4880504596 Enrollment ID: O20031106000287 |
News Archive
The United States Food and Drug Administration (FDA) will be looking at the behavior and health of 40,000 smokers aged 12 and older to study the effects of new tobacco regulations.
A brief period of postnatal visual deprivation, when early in life, drives a rewiring of the brain areas involved in visual processing, even if the visual restoration is completed well before the baby reaches one year of age, researchers at the University of Trento, McMaster University, and the University of Montreal revealed today in Current Biology.
Abraxis BioScience, Inc., a fully integrated, global biotechnology company, today announced that Taiho Pharmaceutical Co., Ltd. has received approval from the Ministry of Health, Labor and Welfare to market ABRAXANE IV Infusion 100 mg, Paclitaxel Injection (Suspension with Albumin), for use in the treatment of breast cancer. The New Drug Application (J-NDA) for ABRAXANE was filed with the Ministry of Health, Labor and Welfare in 2008.
One year after being hospitalized in intensive care, patients have reduced bone mass that puts them at greater risk for fractures, according to a new study published online ahead of print in the American Journal of Respiratory and Critical Care Medicine.
› Verified 2 days ago
Entity Name | Wenatchee Valley Hospital |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1669719688 PECOS PAC ID: 9537309869 Enrollment ID: O20130716000034 |
News Archive
The United States Food and Drug Administration (FDA) will be looking at the behavior and health of 40,000 smokers aged 12 and older to study the effects of new tobacco regulations.
A brief period of postnatal visual deprivation, when early in life, drives a rewiring of the brain areas involved in visual processing, even if the visual restoration is completed well before the baby reaches one year of age, researchers at the University of Trento, McMaster University, and the University of Montreal revealed today in Current Biology.
Abraxis BioScience, Inc., a fully integrated, global biotechnology company, today announced that Taiho Pharmaceutical Co., Ltd. has received approval from the Ministry of Health, Labor and Welfare to market ABRAXANE IV Infusion 100 mg, Paclitaxel Injection (Suspension with Albumin), for use in the treatment of breast cancer. The New Drug Application (J-NDA) for ABRAXANE was filed with the Ministry of Health, Labor and Welfare in 2008.
One year after being hospitalized in intensive care, patients have reduced bone mass that puts them at greater risk for fractures, according to a new study published online ahead of print in the American Journal of Respiratory and Critical Care Medicine.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Geoffrey Harms, MD 820 N Chelan Ave, Wenatchee, WA 98801-2028 Ph: (509) 663-8711 | Geoffrey Harms, MD 1201 S Miller St Ste A, Wenatchee, WA 98801-3201 Ph: (509) 663-8711 |
News Archive
The United States Food and Drug Administration (FDA) will be looking at the behavior and health of 40,000 smokers aged 12 and older to study the effects of new tobacco regulations.
A brief period of postnatal visual deprivation, when early in life, drives a rewiring of the brain areas involved in visual processing, even if the visual restoration is completed well before the baby reaches one year of age, researchers at the University of Trento, McMaster University, and the University of Montreal revealed today in Current Biology.
Abraxis BioScience, Inc., a fully integrated, global biotechnology company, today announced that Taiho Pharmaceutical Co., Ltd. has received approval from the Ministry of Health, Labor and Welfare to market ABRAXANE IV Infusion 100 mg, Paclitaxel Injection (Suspension with Albumin), for use in the treatment of breast cancer. The New Drug Application (J-NDA) for ABRAXANE was filed with the Ministry of Health, Labor and Welfare in 2008.
One year after being hospitalized in intensive care, patients have reduced bone mass that puts them at greater risk for fractures, according to a new study published online ahead of print in the American Journal of Respiratory and Critical Care Medicine.
› Verified 2 days ago
Dr. Ahmad Sabih Musmar, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 933 Red Apple Rd, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Dr. Jonathan Andrew Bolles, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1201 S Miller St Ste A, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Brett J. Hiendlmayr, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1201 S Miller St, Wenatchee, WA 98801 Phone: 509-662-1511 | |
Kevin Joseph Struzzieri, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1201 S Miller St, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Dr. Brent A. Barber, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 933 Red Apple Rd, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Mircea Batanoiu, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 Fax: 509-665-6065 | |
Dr. Mark Douglas Johnson, M.D., MTM&H Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 933 Red Apple Rd, Wenatchee, WA 98801 Phone: 509-665-6210 Fax: 509-667-3310 |